In COPD patient with persistent symptoms on albuterol, which addition is most appropriate for group B?

In COPD patient with persistent symptoms on albuterol, which addition is most appropriate for group B?

• A. Inhaled ipratropium
• B. Inhaled tiotropium
• C. Oral prednisone
• D. Oral theophylline

Answer: (B)

Persistent symptoms in COPD despite using a short-acting bronchodilator point to the need for a maintenance, long-acting bronchodilator. For a patient in Group B, who has substantial symptoms but a low risk of exacerbations, the goal is to improve daily symptoms and function with sustained bronchodilation. Tiotropium is a long-acting muscarinic antagonist inhaled daily, providing ongoing airway bronchodilation, improving dyspnea and exercise tolerance, and reducing future exacerbations compared with relying on short-acting relief alone. That makes inhaled tiotropium the best addition. Inhaled ipratropium is a short-acting anticholinergic and doesn’t offer sustained control for daily symptoms. Oral prednisone isn’t appropriate for stable COPD due to systemic side effects and lack of long-term benefit in this setting. Theophylline is an older agent with a narrow therapeutic window and more adverse effects, not preferred as first-line add-on therapy.

Persistent symptoms in COPD despite using a short-acting bronchodilator point to the need for a maintenance, long-acting bronchodilator. For a patient in Group B, who has substantial symptoms but a low risk of exacerbations, the goal is to improve daily symptoms and function with sustained bronchodilation. Tiotropium is a long-acting muscarinic antagonist inhaled daily, providing ongoing airway bronchodilation, improving dyspnea and exercise tolerance, and reducing future exacerbations compared with relying on short-acting relief alone. That makes inhaled tiotropium the best addition.

Inhaled ipratropium is a short-acting anticholinergic and doesn’t offer sustained control for daily symptoms. Oral prednisone isn’t appropriate for stable COPD due to systemic side effects and lack of long-term benefit in this setting. Theophylline is an older agent with a narrow therapeutic window and more adverse effects, not preferred as first-line add-on therapy.